信立泰：SAL0139药品临床试验申请获得受理

Core Viewpoint - The company has received a notice of acceptance from the National Medical Products Administration for its clinical trial application of the innovative small molecule drug SAL0139, which is intended for the treatment of hyperlipidemia [1] Group 1 - SAL0139 is a small molecule drug developed by the company with independent intellectual property rights [1] - The application submitted is specifically for clinical trials aimed at treating hyperlipidemia, a metabolic disease that can lead to multiple systemic complications if not controlled over time [1] - The company will fulfill its information disclosure obligations regarding subsequent developments as required [1]